Organogenesis Holdings Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
ORGO$0.91+11.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $88,626 | $103,840 |
| Restricted cash | 720 | 498 |
| Accounts receivable, net | 96,148 | 81,999 |
| Inventories, net | 27,694 | 28,253 |
| Prepaid expenses and other current assets | 13,979 | 10,454 |
| Total current assets | 227,167 | 225,044 |
| Property and equipment, net | 114,245 | 116,228 |
| Intangible assets, net | 14,970 | 15,871 |
| Goodwill | 28,772 | 28,772 |
| Operating lease right-of-use assets, net | 38,616 | 40,118 |
| Deferred tax asset, net | 28,002 | 28,002 |
| Other assets | 6,709 | 5,990 |
| Total assets | $458,481 | $460,025 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Current portion of term loan | $5,489 | $5,486 |
| Current portion of finance lease obligations | 1,103 | 1,081 |
| Current portion of operating lease obligations - related party | 8,543 | 8,413 |
| Current portion of operating lease obligations | 4,675 | 4,731 |
| Accounts payable | 23,230 | 30,724 |
| Accrued expenses and other current liabilities | 39,759 | 30,074 |
| Total current liabilities | 82,799 | 80,509 |
| Term loan, net of current portion | 59,371 | 60,745 |
| Finance lease obligations, net of current portion | 1,604 | 1,888 |
| Operating lease obligations, net of current portion - related party | 11,052 | 11,954 |
| Operating lease obligations, net of current portion | 24,383 | 25,053 |
| Other liabilities | 1,242 | 1,213 |
| Total liabilities | 180,451 | 181,362 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued | — | — |
| Common stock, $0.0001 par value; 400,000,000 shares authorized; 133,267,888 and 132,044,944 shares issued; 132,539,340 and 131,316,396 shares outstanding at March 31, 2024 and December 31, 2023, respectively. | 13 | 13 |
| Additional paid-in capital | 321,088 | 319,621 |
| Accumulated deficit | (43,071) | (40,971) |
| Total stockholders’ equity | 278,030 | 278,663 |
| Total liabilities and stockholders’ equity | $458,481 | $460,025 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.